Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma

Journal article

Open access

Peer reviewed

Ola Landgren, Dickran Kazandjian, Ashleigh O'Connell, Gregory Finn and Noopur Raje

Blood, Vol.140(Supplement 1), pp.10172-10173

2022-11-15

Files and links (1)

url

https://doi.org/10.1182/blood-2022-166854View

Published (Version of record) Open

6 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.204 Molecular & Cell Biology - Immunotherapy; 1.204.1334 Phage Display
Web Of Science research areas: Hematology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma
Creators: Ola Landgren - Sylvester Comprehensive Cancer Center
Dickran Kazandjian - Sylvester Comprehensive Cancer Center
Ashleigh O'Connell - Pfizer
Gregory Finn - Pfizer
Noopur Raje - Massachusetts General Hospital
Publication Details: Blood, Vol.140(Supplement 1), pp.10172-10173
Publisher: Elsevier Inc
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031786675702976